Darinaparsin · Darvias
Small molecule
Also known as ZIO-101
Evidence outlook
Approved: Relapsed or refractory peripheral T-cell lymphoma (DARVIAS Injection 135 mg) (JP)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Weak signal
Also approved (1)
- Relapsed or refractory peripheral T-cell lymphoma (DARVIAS Injection 135 mg)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02653976 NCT02653976 · Peripheral T-Cell Lymphoma The study was single-arm, open-label, and had no placebo or active comparator; 65 patients were treated, with 57 included in the central tumor-response analysis. The clinical response endpoint was reported, but a treatment-versus-control comparison was not possible, so the observed response rate cannot establish comparative effectiveness. Registry: NCT02653976 | 2 | Tumor Response (Central Assessment) (Central assessments of tumor response were performed every 3 cycles, and/or at the end of treatment visit, during 6-cycle treatment period. The best response was determined during 6-cycle treatment period. Maximum duration of assessments was 5.3 months.) 2020-10-11 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Peripheral T-Cell Lymphoma: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Darinaparsin (Darvias): this drug | Phase 2 | Small molecule | apoptosis via reactive oxygen species (ROS) generation and mitochondrial disruption | Weak signal | No reviewed efficacy summary in this indication | |
| Belinostat | Approved | Small molecule | Histone Deacetylase Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Brentuximab Vedotin | Approved | Antibody–drug conjugate | Anti-CD30 antibody-drug conjugate | not yet graded | No reviewed efficacy summary in this indication | |
| Chidamide | Phase 3 | Small molecule | HDAC | not yet graded | No reviewed efficacy summary in this indication | |
| Soquelitinib | Phase 3 | Small molecule | ITK | not yet graded | No reviewed efficacy summary in this indication | |
| Valemetostat Tosylate (Ezharmia) | Phase 2 | Small molecule | EZH1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Zeprumetostat | Phase 2 | Small molecule | EZH1/2 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.